We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck, Eisai Get Full Approval for Keytruda-Lenvima Combination
Merck, Eisai Get Full Approval for Keytruda-Lenvima Combination
The FDA has granted full approval for Merck’s blockbuster cancer drug Keytruda (pembrolizumab) in combination with Merck and Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) for treating advanced endometrial carcinoma.